Is Atai Life Sciences N.V. (ATAI) Price Targeted To Increase?

As of Friday close, Atai Life Sciences N.V.’s (NASDAQ:ATAI) stock was up $0.27, moving up 6.57 percent to $4.38. The average number of shares traded per day over the past five days has been 872,860 shares. 4 times new highs have been achieved over the past 5 days, with a $0.52 gain in that time frame. In the last twenty days, the average volume was 888,925, while in the previous 50 days, it was 842,340.

Since last month, ATAI stock rose 2.58%. Shares of the company fell to $3.51 on 08/02/22, the lowest level in the past month. A 52-week high of $17.90 was reached on 01/03/22 after having rallying from a 52-week low of $2.95. Since the beginning of this year, ATAI’s stock price has dropped by -42.60% or -$3.25, and marked a new high 1 time. However, the stock has declined by -75.53% since its 52-week high.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Atai Life Sciences N.V. (ATAI) last reported insider trading activity 99 days ago on Apr 29. Apeiron Investment Group Ltd., the 10% Owner of the company, purchased of 21,900 shares for $4.47 on Apr 29. It resulted in a $97,801 investment by the insider. Apeiron Investment Group Ltd. added 34,700 shares at an average price of $4.46 on Apr 28. The insider now owns 1,777,402 shares following the transaction. On Apr 27, 10% Owner Apeiron Investment Group Ltd. bought 19,803 shares at $4.64 apiece. The transaction was valued at $91,939.

Valuation Metrics

The latest dividend of $6.00 per share was paid out, which is 1363.41% more than last year’s $0.41.

Financial Health

In the three months ended March 30, Atai Life Sciences N.V.’s quick ratio stood at 15.80, while its current ratio was 15.80, showing that the company is able to pay off its debt. Based on annual data, ATAI earned $156.18 million in gross profit and brought in $20.38 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -35.00%. Return on equity (ROE) for the past 12 months was -49.80%.

While analysts expected Atai Life Sciences N.V. to report -$0.24 quarterly earnings, the actual figure was -$0.24 per share. During the quarter, the company generated -$33.38 million in EBITDA. The liabilities of Atai Life Sciences N.V. were 29.38 million at the end of its most recent quarter ended March 30, and its total debt was $0.72 million. The value of shareholders’ equity is $160.73 million.

Technical Picture

This quick technical analysis looks at Atai Life Sciences N.V.’s (ATAI) price momentum. With a historical volatility rate of 73.89%, the RSI 9-day stood at 65.50% on 05 August.

With respect to its five-day moving average, the current Atai Life Sciences N.V. price is up by +13.47% percent or $0.52. At present, ATAI shares trade +1.62% above its 20-day simple moving average and -13.61% percent below its 100-day simple moving average. However, the stock is currently trading approximately +16.18% above its SMA50 and -70.12% below its SMA200.

Stochastic coefficient K was 65.33% and Stochastic coefficient D was 46.56%, while ATR was 0.26. Given the Stochastic reading of 87.00% for the 14-day period, the RSI (14) reading has been calculated as 60.99%. As of today, the MACD Oscillator reading stands at 0.25, while the 14-day reading stands at 0.19.

Analyst Ratings

Maxim Group launched its rating on Atai Life Sciences N.V. (NASDAQ: ATAI) to a Buy in a note to investors on November 30, 2021. Atai Life Sciences N.V. (ATAI) has been rated Buy by analysts. According to 0 brokerage firms, ATAI is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Atai Life Sciences N.V. stock as buy, with 10 recommending it as overweight.

With a median target price of $22.00, the current consensus forecast for the stock is $6.60 – $50.00. Based on these forecasts, analysts predict Atai Life Sciences N.V. (ATAI) will achieve an average price target of $25.18.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]